6月19日，1药网将披露2025财年一季报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实 际披露日期以公司公告为准）。 7月1日，1药网(YI)盘中上涨5.02%，截至00:03，报7.278美元/股，成交8.69万美元，总市值6308.25万美 元。 财务数据显示，截至2024年12月31日，1药网收入总额144.01亿人民币，同比减少3.66%；归母净利 润-6474.3万人民币，同比增长83.51%。 大事提醒： 1药网旗下拥有:B2C医药平台"1药网"、互联网医院"1诊",B2B医药平台"1药城",通过创新的S2B2C的模 式,全面实现B端和C端、线上和线下、自营和平台、医+药+保险的融合发展。2018年,1药网成功登陆美 国纳斯达克,股票代码"YI",成为中国互联网医药健康赴美上市第一股。 本文源自金融界 资料显示，1药网公司是111集团的境外控股公司。1药网由于刚和刘峻岭于2010年创建,是中国互联网医 药健康的领军企业,致力于用数字科技将患者和药品及医疗服务有机连接,打造中国最大的医药健康平 台。 1药网基于在互联网科技、智能供应链、全渠道药品商业化、云服务方面建立的优势,与药企、药品 ...

Core Viewpoint - 1药网 (YI) has experienced a slight increase in stock price, while its financial performance shows a decline in revenue but a significant increase in net profit [1][2]. Financial Performance - As of December 31, 2024, 1药网 reported total revenue of 14.401 billion RMB, a year-on-year decrease of 3.66% [1]. - The net profit attributable to the parent company was -64.743 million RMB, reflecting a year-on-year increase of 83.51% [1]. Company Overview - 1药网 is a leading player in China's internet healthcare sector, founded in 2010 by Liu Junling, and is a subsidiary of 111 Group [2]. - The company aims to connect patients with pharmaceuticals and medical services through digital technology, establishing itself as the largest healthcare platform in China [2]. - 1药网 operates various platforms, including the B2C pharmaceutical platform "1药网," the internet hospital "1诊," and the B2B pharmaceutical platform "1药城," utilizing an innovative S2B2C model [2]. - The company went public on NASDAQ in 2018, becoming the first Chinese internet healthcare company to list in the U.S. [2].

Core Viewpoint - 111, Inc. reported stable net revenues of RMB 3.5 billion (US$486.3 million) for Q1 2025, reflecting resilience in a challenging macroeconomic environment [4][5][7] - The company achieved a 4.8% year-over-year reduction in total operating expenses, improving operational efficiency [4][7][19] - The strategic focus remains on leveraging technology to enhance the healthcare value chain, with continued investments in AI and digital solutions [4][5] Financial Performance - Net revenues for Q1 2025 were RMB 3,529 million (US$486.3 million), a slight increase of 0.02% from RMB 3,528 million in Q1 2024 [5][31] - Gross segment profit decreased by 6.4% year-over-year to RMB 195.1 million (US$26.9 million) due to unfavorable macroeconomic conditions [5][31] - Operating expenses totaled RMB 195.0 million (US$26.9 million), down 4.8% from RMB 204.8 million in the same quarter last year, with operating expenses as a percentage of net revenues decreasing to 5.5% [7][9][19] Operational Highlights - The company maintained quarterly operational profitability with income from operations of RMB 0.1 million (US$0.02 million), down from RMB 3.7 million in the same quarter last year [7][11] - Non-GAAP income from operations was RMB 4.3 million (US$0.6 million), compared to RMB 8.9 million in the same quarter of last year [12][32] - Net cash from operating activities was RMB 112.6 million (US$15.5 million), indicating positive operating cash flow for the quarter [7][31] Cost Management - Selling and marketing expenses decreased by 15.5% year-over-year to RMB 67.9 million (US$9.4 million) [9][10] - Technology expenses were reduced by 15.6% to RMB 15.5 million (US$2.1 million) [19] - General and administrative expenses decreased by 3.8% to RMB 18.3 million (US$2.5 million) [19] Balance Sheet and Cash Position - As of March 31, 2025, the company held cash and cash equivalents, restricted cash, and short-term investments totaling RMB 556.8 million (US$76.7 million), an increase from RMB 518.3 million at the end of 2024 [17][29] - Total current assets decreased to RMB 2,485.2 million (US$342.5 million) from RMB 2,649.7 million at the end of 2024 [29] - Total liabilities decreased to RMB 2,230.0 million (US$307.3 million) from RMB 2,406.9 million at the end of 2024 [29]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR For the transition period from to . Commission file number: 001-38639 111, Inc. (Exact name of Registrant as specified in its charter) N/A (Translation of Registrant's na ...

111, Inc. (NASDAQ:YI) Q4 2024 Earnings Conference Call March 20, 2025 7:30 AM ET Company Participants Junling Liu - Co-Founder, Chairman and Chief Executive Officer Luke Chen - Chief Financial Officer Haihui Wang - Chief Operating Officer Conference Call Participants Robert Sassoon - Water Tower Research Shifan Sun - CICC Zoe Bian - Citi Operator Hello, everyone, and thank you for joining 111's Conference Call today. On the call today from the company are Dr. . Gang Yu, Co-Founder and Executive Chairman; Mr ...

111, Inc. (NASDAQ: YI) Reshaping the Value Chain of Healthcare Industry with Digital Technology Fourth Quarter and Fiscal Year 2024 Earnings Call March 20, 2025 1 DISCLAIMER 2 Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company's ability comply with extensive and evolving regulatory ...

111 (YI) Q4 2024 Earnings Call March 20, 2025 07:30 AM ET Company Participants Junling Liu - Co-Founder, Acting CFO, Chairman & CEOYang Chen - Senior Finance Executive & DirectorHaihui Wang - Co-Chief Operating Officer Conference Call Participants Robert Sassoon - Senior Research AnalystNone - Analyst Operator Hello, everyone, and thank you for joining one hundred and eleven's conference call today. On the call today from the company are Doctor. Gang Yu, Co Founder and Executive Chairman Mr. Junling Liu, Co ...

Core Viewpoint - 111, Inc. achieved its first-ever annual operational profitability and positive operating cash flow in 2024, despite facing challenges from the macroeconomic environment and healthcare reforms [4][7][20]. Fourth Quarter 2024 Highlights - Net revenues for Q4 2024 were RMB3.8 billion (US$527.1 million), a decrease of 6.3% from RMB4.1 billion in Q4 2023 [5][7]. - Total operating expenses in Q4 2024 were RMB209.8 million (US$28.7 million), a significant improvement of 50.1% compared to RMB420.8 million in Q4 2023 [7][9]. - Loss from operations improved to RMB7.3 million (US$1.0 million) in Q4 2024, a 96.5% improvement from RMB206.5 million in the same quarter of 2023 [10][12]. - Non-GAAP loss from operations was RMB2.3 million (US$0.3 million), improving by 95.8% from RMB55.2 million in Q4 2023 [11][13]. Fiscal Year 2024 Highlights - Total net revenues for the fiscal year 2024 were RMB14.4 billion (US$2.0 billion), down 3.7% from RMB14.9 billion in 2023 [17][21]. - Income from operations for the full year was RMB2.1 million (US$0.3 million), a turnaround from an operating loss of RMB350.1 million in 2023 [20][21]. - Non-GAAP income from operations for 2024 was RMB22.3 million (US$3.0 million), compared to a non-GAAP loss of RMB123.9 million in 2023 [21][22]. - Net cash from operating activities reached RMB263.0 million (US$36.0 million), marking the first-ever positive operating cash flow for the year [7][21]. Operational Efficiency - The company focused on operational efficiency, with total operating expenses as a percentage of revenues decreasing by 230 basis points to 5.7% for the full year 2024 [4][7]. - In Q4 2024, operating expenses accounted for 5.5% of revenues, down 470 basis points year over year [4][7]. - The company streamlined logistics and reduced delivery times through its Kunpeng Network, which operates 28 transportation routes across five major geographic hubs [4][7]. Future Outlook - The company remains optimistic about long-term growth opportunities driven by the digitalization of healthcare and the rising healthcare needs of China's aging population [4][7]. - Continued investments in AI and digital technologies are planned to enhance operational efficiency and customer engagement [4][7].

Core Viewpoint - 111, Inc. is set to participate in a fireside chat to discuss its Q4 2024 earnings, priorities for 2025, and macroenvironment overview [1][2]. Company Overview - 111, Inc. is a leading tech-enabled healthcare platform in China, focused on reshaping the healthcare value chain by digitally empowering both upstream and downstream sectors [4]. - The company provides consumers with access to pharmaceutical products and healthcare services through its online retail pharmacy, 1 Pharmacy, and an offline virtual pharmacy network [4]. - Online healthcare services are offered through its internet hospital, 1 Clinic, which includes online consultations, electronic prescriptions, and patient management [4]. - 111 operates the largest virtual pharmacy network in China, enhancing service delivery for offline pharmacies with cloud-based solutions [4]. - The company also provides an omni-channel drug commercialization platform, offering services like digital marketing, patient education, data analytics, and pricing monitoring to strategic partners [4]. Upcoming Events - The fireside chat will take place on March 26, 2025, at 11:00 a.m. ET, featuring Mr. Junling Liu, the Co-Founder, Chairman, and CEO of 111 [2]. - The Q4 2024 earnings report is scheduled for March 20, 2024 [2]. - Registration for the event is available through a provided link, and a replay will be accessible on the company's investor relations website [2].

Core Viewpoint - 111, Inc. is set to report its unaudited financial results for the fourth quarter and fiscal year 2024 on March 20, 2025, indicating a focus on transparency and communication with investors [1]. Company Overview - 111, Inc. is a leading tech-enabled healthcare platform in China, aiming to reshape the healthcare value chain by digitally empowering both upstream and downstream sectors [4]. - The company provides consumers with improved access to pharmaceutical products and healthcare services through its online retail pharmacy, 1 Pharmacy, and its offline virtual pharmacy network [4]. - 111, Inc. also offers online healthcare services via its internet hospital, 1 Clinic, which includes online consultations, electronic prescriptions, and patient management services [4]. - The company operates 1 Medicine, an online platform that serves as a one-stop shop for pharmacies to source a wide range of pharmaceutical products [4]. - With the largest virtual pharmacy network in China, 111, Inc. enhances the ability of offline pharmacies to serve customers through cloud-based services [4]. - The company provides an omni-channel drug commercialization platform to strategic partners, offering services such as digital marketing, patient education, data analytics, and pricing monitoring [4]. Earnings Conference Call - The management team will host an earnings conference call on March 20, 2025, at 7:30 AM U.S. Eastern Time, allowing stakeholders to engage directly with the company's financial performance [2]. - Participants must register in advance to receive dial-in information, ensuring organized communication during the call [2][3]. - A live and archived webcast of the conference call will be available on the company's website, providing additional access to the information shared [3].